FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

Regulatory Approvals — FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer  Targeted Oncology

Read the original at Regulatory Approvals ↗

Auto-published by the finit.news Events monitor from Regulatory Approvals; summarized by AI and may contain errors — verify against the primary source. August 26, 2026.

By